Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$5.1 - $7.0 $901,083 - $1.24 Million
-176,683 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$5.32 - $7.37 $980,327 - $1.36 Million
-184,272 Reduced 51.05%
176,683 $1.16 Million
Q2 2021

Aug 16, 2021

BUY
$4.78 - $7.96 $95,638 - $159,263
20,008 Added 5.87%
360,955 $2.4 Million
Q1 2021

May 17, 2021

SELL
$5.49 - $9.36 $685,415 - $1.17 Million
-124,848 Reduced 26.8%
340,947 $1.95 Million
Q4 2020

Feb 12, 2021

SELL
$8.13 - $12.79 $1.04 Million - $1.64 Million
-128,072 Reduced 21.57%
465,795 $4.16 Million
Q3 2020

Nov 12, 2020

BUY
$11.64 - $16.3 $3.06 Million - $4.29 Million
263,120 Added 79.55%
593,867 $6.91 Million
Q2 2020

Aug 14, 2020

BUY
$5.38 - $16.14 $156,138 - $468,415
29,022 Added 9.62%
330,747 $5.3 Million
Q1 2020

May 12, 2020

SELL
$4.2 - $13.0 $14,418 - $44,629
-3,433 Reduced 1.12%
301,725 $1.81 Million
Q4 2019

Feb 14, 2020

BUY
$11.13 - $16.28 $6,043 - $8,840
543 Added 0.18%
305,158 $4.03 Million
Q3 2019

Nov 15, 2019

BUY
$9.79 - $16.72 $281,893 - $481,435
28,794 Added 10.44%
304,615 $3.78 Million
Q2 2019

Aug 14, 2019

BUY
$15.1 - $31.25 $2.81 Million - $5.81 Million
185,778 Added 206.32%
275,821 $4.44 Million
Q1 2019

May 14, 2019

SELL
$24.38 - $34.71 $156,202 - $222,386
-6,407 Reduced 6.64%
90,043 $2.83 Million
Q4 2018

Feb 13, 2019

SELL
$24.21 - $48.01 $104,393 - $207,019
-4,312 Reduced 4.28%
96,450 $3.17 Million
Q3 2018

Nov 13, 2018

BUY
$20.86 - $33.33 $69,818 - $111,555
3,347 Added 3.44%
100,762 $3.09 Million
Q2 2018

Aug 15, 2018

BUY
$25.0 - $27.75 $2.44 Million - $2.7 Million
97,415 New
97,415 $2.61 Million

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $198M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Granahan Investment Management, LLC Portfolio

Follow Granahan Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Granahan Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Granahan Investment Management, LLC with notifications on news.